Sybille Baumann

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

Journal: Nature

Published: July 16, 2025

Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study.

Safety, Tolerability, and Pharmacokinetics of Filapixant, a Highly Selective P2X3 Receptor Antagonist, in an Ascending-Single-Dose First-in-Human Study.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 13, 2025

Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey.

Non-alcoholic fatty liver disease in obese subjects as related to increasing insulin resistance and deteriorating glucose control: Three years of follow-up from a longitudinal survey.

Journal: Journal of diabetes and metabolic disorders

Published: October 08, 2023

Cardiovascular risk of veterans' football: An observational cohort study with follow-up.

Cardiovascular risk of veterans' football: An observational cohort study with follow-up.

Journal: PloS one

Published: September 15, 2022

First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

Journal: British journal of clinical pharmacology

Published: October 12, 2021

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

Journal: Nature

Published: December 09, 2020

Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.

Desmethyl bosentan displays a similar in vitro interaction profile as bosentan.

Journal: Pulmonary pharmacology & therapeutics

Published: September 01, 2014

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial.

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial.

Journal: SpringerPlus

Published: April 10, 2014

An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.

An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.

Journal: International journal of clinical pharmacology and therapeutics

Published: April 25, 2013

Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

Journal: Clinical drug investigation

Published: April 23, 2013

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers.

Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers.

Journal: European journal of clinical pharmacology

Published: January 31, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026